Effects of cicletanine on the urinary excretion of prostanoids and kallikrein, and on renal function in man

Kazuo Tsunoda, Keishi Abe, Ken Omata, Takeshi Hagino, Naoyoshi Minami, Masanori Munakata, Kazunori Yoshida, Hiromichi Sakuma, Seiichi Misawa, Syuuji Arima, Yutaka Imai, Kaoru Yoshinaga

Research output: Contribution to journalArticlepeer-review


The effects of cicletanine, a new antihypertensive agent, on the prostaglandin-kallikrein system and the reninangiotensin system were studied. A single oral dose of 200 mg cicletanine or placebo was administered to 9 healthy male volunteers, with samples of blood and urine obtained before and 2 hours after drug administration. Cicletanine increased the urine flow, urinary excretion of sodium, and fractional excretion of sodium by 47%, 115%, and 104%, respectively. While the excretion of 6-keto-prostaglandin-F1α was enhanced significantly, urinary excretion of thromboxane-B2, prostaglandin-E2, and kallikrein were unchanged. Cicletanine also did not alter plasma renin activity, plasma aldosterone concentration, or creatinine clearance. These observations suggest that cicletanine may suppress sodium reabsorption at the nephron, and it may stimulate prostacyclin generation with no effect on that of thromboxane-A2. Thus cicletanine may be beneficial in the management of cardiovascular disorders in which the equilibrium between prostacyclin and thromboxane is disturbed.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalCardiovascular Drugs and Therapy
Issue number2
Publication statusPublished - 1993 Apr 1


  • cicletanine
  • kallikrein
  • natriuresis
  • prostacyclin
  • thromboxane

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Effects of cicletanine on the urinary excretion of prostanoids and kallikrein, and on renal function in man'. Together they form a unique fingerprint.

Cite this